Last update 25 May 2025

TBX-3400

Overview

Basic Info

Drug Type
Cell therapy
Synonyms
autologous human peripheral blood mononuclear cells incubated ex vivo with protein TBX-4000 (Tat-MYC), TBX 3400, TBX-3400
Target-
Action
modulators
Mechanism
Cell replacements, Immunologic cytotoxicity, Immunomodulators
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Melanoma
Inactive Indication
Malignant melanoma, metastaticRefractory Cancer
Originator Organization
Taiga Biotechnologies, Inc.Taiga Biotechnologies, Inc.
Active Organization
Taiga Biotechnologies, Inc.Taiga Biotechnologies, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with TBX-3400
NCT04640246
/ Unknown statusPhase 1/2
A Phase 1/2 Multi-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies
NCT03385486
/ Unknown statusPhase 1
A Phase 1 Multi-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
100 Clinical Results associated with TBX-3400
Login to view more data
100 Translational Medicine associated with TBX-3400
Login to view more data
100 Patents (Medical) associated with TBX-3400
Login to view more data
100 Deals associated with TBX-3400
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MelanomaPhase 2
United States
Taiga Biotechnologies, Inc.Taiga Biotechnologies, Inc.
22 Jul 2022
Refractory CancerPhase 2
United States
Taiga Biotechnologies, Inc.Taiga Biotechnologies, Inc.
25 Jan 2021
Refractory CancerPhase 2
Israel
Taiga Biotechnologies, Inc.Taiga Biotechnologies, Inc.
25 Jan 2021
Solid tumorPhase 2
Israel
Taiga Biotechnologies, Inc.Taiga Biotechnologies, Inc.
25 Jan 2021
Malignant melanoma, metastaticPhase 1
United States
Taiga Biotechnologies, Inc.Taiga Biotechnologies, Inc.
02 Jun 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free